Last reviewed · How we verify
Drisdol (ERGOCALCIFEROL)
Drisdol (Ergocalciferol) is a provitamin D2 compound developed by Sanofi Aventis US and currently owned by Esjay Pharma. It targets the 25-hydroxyvitamin D-1 alpha hydroxylase enzyme and is used to treat various bone disorders, including rickets, osteoporosis, and hypocalcemia. Drisdol is a small molecule modality that has been FDA-approved since 1941 and is now available as a generic medication. It is used to treat a range of conditions, including familial x-linked hypophosphatemic vitamin D refractory rickets, glucocorticoid-induced osteoporosis, and hyperparathyroidism secondary to chronic renal failure. Drisdol is off-patent and has multiple generic manufacturers.
At a glance
| Generic name | ERGOCALCIFEROL |
|---|---|
| Sponsor | Esjay Pharma |
| Drug class | Provitamin D2 Compound [EPC] |
| Target | 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1941 |
Approved indications
- Familial x-linked hypophosphatemic vitamin D refractory rickets
- Glucocorticoid Induced Osteoporosis
- Hyperparathyroidism Secondary to Chronic Renal Failure with Dialysis
- Hypocalcemia
- Hypogonadal Osteoporosis in Males
- Hypoparathyroidism
- Osteomalacia
- Osteoporosis
- Postmenopausal osteoporosis
- Prevention of dental caries
- Rickets
- Vitamin D Dependent Rickets
- Vitamin D deficiency
- Vitamin Deficiency Prevention
- Vitamin deficiency
Common side effects
- Irreversible renal insufficiency
- Hypertension
- Nephrocalcinosis
- Generalized vascular calcification
- Mental retardation
- Widespread calcification of the soft tissues
- Bone demineralization (osteoporosis)
- Dwarfism
- Vague aches
- Stiffness
- Weakness
- Nausea
Key clinical trials
- Frequency of Fibromyalgia Syndrome in Elderly Patients Aged 80 and Above and Its Relationship With Geriatric Parameters
- Immune Mechanisms of Vitamin D to Reduce Chronic Pain After Burn (PHASE2)
- Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease (PHASE2)
- High-Dose vs Standard Ergocalciferol for Vitamin D Normalization in Aggressive Non-Hodgkin Lymphoma (NA)
- Vitamin D Homeostasis in Sarcoidosis (PHASE4)
- Vitamin D Deficiency in Adults Following a Major Burn Injury (PHASE4)
- Vitamin D Supplementation on Reported Rates of Taxane-Induced Neuropathy (PHASE2)
- Relationship Between Serum Vitamin D and Atherosclerosis in Hemodialysis Patients
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Drisdol CI brief — competitive landscape report
- Drisdol updates RSS · CI watch RSS
- Esjay Pharma portfolio CI